Hodgkin lymphoma (HL) is a highly curable form of cancer, and current treatment regimens are focused on improving treatment efficacy while decreasing the risk of late effects of treatment. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for pediatric HL provide recommendations on the workup, diagnostic evaluation, and treatment of classic HL, including principles of pathology, imaging, staging, systemic therapy, and radiation therapy. This portion of the NCCN Guidelines focuses on the management of pediatric classic HL in the upfront and relapsed/refractory settings.

No abstract

CCS may have iron overload. Overall prevalence is low. At-risk include teenagers at diagnosis and those receiving higher total PRBC volumes.

No abstract

No abstract

In December 2019, a novel coronavirus (Sars-CoV-2) emerged from Wuhan, Hubei province, China, and has spread worldwide, with more than 4 million confirmed cases[1,2,3]. Available literature on the clinical characteristics and natural history of pediatric patients infected with Sars-CoV-2 is limited and less has been established regarding guidelines for the treatment of immunocompromised pediatric patients. This is a case report on the clinical course and management of a 6 year old female with acute lymphoblastic lymphoma with Sars-CoV-2. The goal is to highlight the need for management guidelines in the care of pediatric cancer patients with Sars-CoV-2.

Background Vitamin D deficiency and insufficiency have been associated with poorer health outcomes. Children with cancer are at high risk for vitamin D deficiency and insufficiency. At our institution, we identified high variability in vitamin D testing and supplementation in this population. Of those tested, 65% were vitamin D deficient/insufficient. We conducted a quality improvement (QI) initiative with aim to improve vitamin D testing and supplementation among children aged 2–18 years with newly diagnosed cancer to ≥80% over 6 months. Methods An inter‐professional team reviewed baseline data, then developed and implemented interventions using Plan‐Do‐Study‐Act (PDSA) cycles. Barriers were identified using QI tools, including lack of automated triggers for testing and inconsistent supplementation criteria and follow‐up testing post supplementation. Interventions included an institutional vitamin D guideline, clinical decision‐making tree for vitamin D deficiency, insufficiency and sufficiency, electronic medical record triggers, and automated testing options. Results Baseline: N = 26 patients, four (15%) had baseline vitamin D testing; two (8%) received appropriate supplementation. Postintervention: N = 33 patients; 32 (97%) had baseline vitamin D testing; 33 (100%) received appropriate supplementation and completed follow‐up testing timely (6–8 weeks post supplementation). Change was sustained over 24 months. Conclusions We achieved and sustained our aim for vitamin D testing and supplementation in children with newly diagnosed cancer through inter‐professional collaboration of hematology/oncology, endocrinology, hospital medicine, pharmacy, nursing, and information technology. Future PDSA cycles will address patient compliance with vitamin D supplementation and impact on patients’ vitamin D levels.

No abstract